Laurent Claisse
CEO, Clean Biologics
False
Advertisement
Why Early QC Planning Matters in Cell and Gene Therapy
June 30, 2026
Late-stage CMC setbacks often begin with early QC decisions that shape cell and gene therapy timelines, costs, and regulatory outcomes
7 min read
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
